These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23594109)

  • 21. Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
    Schernthaner G; Chilton RJ
    Diabetes Obes Metab; 2010 Dec; 12(12):1023-35. PubMed ID: 20977573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
    Garratt KN; Brady PA; Hassinger NL; Grill DE; Terzic A; Holmes DR
    J Am Coll Cardiol; 1999 Jan; 33(1):119-24. PubMed ID: 9935017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas?
    Koufakis T; Dimitriadis G; Kotsa K
    J Diabetes; 2020 Jul; 12(7):499-502. PubMed ID: 32202061
    [No Abstract]   [Full Text] [Related]  

  • 24. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
    White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
    Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Martelli D; Mannucci E
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():57-64. PubMed ID: 22106978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.
    Rao AD; Kuhadiya N; Reynolds K; Fonseca VA
    Diabetes Care; 2008 Aug; 31(8):1672-8. PubMed ID: 18458139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
    Sillars B; Davis WA; Hirsch IB; Davis TM
    Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
    Lamanna C; Monami M; Marchionni N; Mannucci E
    Diabetes Obes Metab; 2011 Mar; 13(3):221-8. PubMed ID: 21205121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Bonora BM; Avogaro A; Fadini GP
    Acta Diabetol; 2019 Sep; 56(9):1051-1060. PubMed ID: 30993527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
    Juurlink DN; Gomes T; Shah BR; Mamdani MM
    Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
    Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
    CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
    Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
    Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas].
    Gonçalves JV; Caldeira J
    Rev Port Cardiol; 2001 Apr; 20(4):439-45. PubMed ID: 11433889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction.
    Halkin A; Roth A; Jonas M; Behar S
    J Thromb Thrombolysis; 2001 Oct; 12(2):177-84. PubMed ID: 11729370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.